AllSci News
PrecisionLife and Ovation collaborate on AI-driven GLP-1 stratification test
PrecisionLife and Ovation have entered a collaboration agreement to commercialize a GLP-1 stratification test platform combining AI-driven genomic analytics...
Pfizer-backed Storm Therapeutics closes USD 56m Series C for RNA drug in sarcoma
STORM Therapeutics, a Cambridge, UK-based clinical-stage biotechnology company focused on targeting RNA modifications to treat cancer, has closed a USD 56...
Boehringer Ingelheim, Zai Lab to try out dual DLL3-targeting combo for SCLC, NECs
Boehringer Ingelheim and China-based Zai Lab (NASDAQ: ZLAB; HKEX: 9688; Shanghai/Cambridge, Mass.) announced a clinical collaboration to evaluate a dual DLL3-targeting cancer…
Sedogen LLC secures US patent for diazoxide formulations treating Prader-Willi syndrome
Sedogen LLC (USA), a parent-led biopharmaceutical company focused on Prader-Willi syndrome, announced the issuance of US Patent 12,589,098 by the US Patent…
Dogwood/Serpin's LRP1 agonist gets FDA IND nod for chemotherapy-induced neuropathy
Dogwood Therapeutics (Nasdaq: DWTX) announced on April 15, 2026 that the US FDA has accepted an investigational new drug application for SP16, an...
New research reveals tau seed propagation patterns in Alzheimer's
Researchers at the University of Alabama at Birmingham, working with collaborators at Rush University Medical Center in Chicago and SUNY Upstate Medical...
Beeline Medicines debuts with USD 300m Series A and BMS autoimmune therapies
Beeline Medicines Corporation, a clinical-stage biotechnology company headquartered in Stamford, Connecticut, has publicly debuted with a USD 300 million...
Terremoto closes USD 108 million Series C financing for AKT1 inhibitors
Terremoto Biosciences, a clinical-stage biotechnology company based in South San Francisco, has closed a USD 108 million Series C financing round to advance...
Telix Pharma raises USD 600m in convertible bond offering
Australia-based Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) announced a USD 600 million convertible bond offering on April 14, 2026, executing a...
Spiral Therapeutics closes USD 27m Series B to advance inner ear disorder treatments
Spiral Therapeutics, a clinical-stage biotechnology company based in South San Francisco focused on inner ear disorders, has closed a USD 27 million Series...
J&J's Q1'25 Earnings Call: Icotyde and JNJ-4804's immunology pathway in focus
J&J's ICOTYDE and JNJ-4804 Emerge as Central Pipeline Signals in JNJ Q1 2026 Earnings
Arbutus Biopharma's imdusiran hepatitis B therapy takes FDA Fast Track status
Arbutus Biopharma announced on April 15, 2026 that the US FDA granted Fast Track designation for imdusiran (AB-729) for the treatment of chronic hepatitis B...
Immorna's posts early positive data for in vivo CAR-T in systemic sclerosis
Immorna, a Hangzhou-based clinical-stage biotechnology company, reported early clinical data for JCXH-213, its CD19-targeted in vivo CAR-T candidate, in a...
Revolution Medicines raises USD 2b in concurrent public offerings
Revolution Medicines, Inc. (Nasdaq: RVMD), a Redwood City, California-based oncology company focused on RAS-addicted cancer therapies, announced concurrent...
Traws Pharma raises USD 60m in private placement financing
Traws Pharma, Inc. (Nasdaq: TRAW), a clinical-stage biopharmaceutical company based in Newtown, Pennsylvania, announced a private placement financing of up...
The AllSci Brief
Systematic R&D and deal news. Daily.